Impact of gut bacteria on survival in patients with cardiogenic shock
Influence of Enteral Microbiome Composition and Microbiome Dependent Metabolites on Mortality of Patients With Cardiogenic Shock
This study looks at how gut bacteria might affect survival rates in adults with cardiogenic shock to see if they can help or hurt recovery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Essen Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Essen, NRW) |
| Trial ID | NCT06006754 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the relationship between the enteral microbiome and mortality rates in patients experiencing cardiogenic shock. It aims to understand how microbial colonization and microbiome-dependent metabolites influence disease progression and outcomes in this critical condition. By analyzing patients over 18 years old who exhibit signs of cardiogenic shock, the study seeks to uncover potential protective or harmful effects of the microbiome on cardiovascular health.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old who show signs of cardiogenic shock, including elevated lactate levels and organ dysfunction.
Not a fit: Patients who are pregnant, undergoing antibiotic treatment, or have certain gastrointestinal disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new insights that improve survival rates and treatment strategies for patients with cardiogenic shock.
How similar studies have performed: While the role of the microbiome in various health conditions is being explored, this specific focus on cardiogenic shock is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * \>18y * signs of cardiogenic shock regardless of etiology * lactate \>3mmol/L * and signs of organ dysfunction (urine output \<30 ml/h, cold extremities, altered mental status) * and systolic blood pressure \<90 mmHg for \>30 minutes or need for vasopressor therapy Exclusion Criteria: * pregnancy/lactation period * antibiotic treatment within \>24h * chronic inflammatory bowel disease * short bowel syndrome * artificial bowel outlet * persistent diarrhea or vomiting in the past 3 months * simultaneous participation in another interfering nutrition study * active chemo or radiation therapy
Where this trial is running
Essen, NRW
- University Hospital Essen — Essen, Nrw, Germany (Recruiting)
Study contacts
- Study coordinator: Christos Rammos, Prof. Dr.
- Email: christos.rammos@uk-essen.de
- Phone: 0049201723
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.